Date: 2013-04-10
Type of information: R&D agreement
Compound: therapeutic peptides
Company: Ipsen (France) Peptidream (Japan)
Therapeutic area: Hormonal diseases - Endocrine diseases
Type agreement: R&D
licensing
Action mechanism:
Disease: undisclosed
Details: * On October 7, 2013, PeptiDream, a Tokyo-based pharmaceutical company,and Ipsen have announced that they have expanded the scope of their April 2013 research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen. The existing collaboration, which combines PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D, will now be extended in scope to enable further therapeutic peptide candidates to enter R&D for additional serious endocrinologic disease.The details of the financial terms of the expanded agreement are not disclosed but are based on those of the existing collaboration.
* On April 10, 2013, PeptiDream and Ipsen have entered into a research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen. The research collaboration will combine PeptiDream’s proprietary peptide library with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D.
Financial terms: Financial terms of the agreement are not disclosed. In exchange for world-wide rights to the therapeutic peptides resulting from the collaboration, Ipsen will make an upfront payment to PeptiDream and pay R&D and commercialization costs. PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
Latest news:
